stoxline Quote Chart Rank Option Currency Glossary
  
Senti Biosciences, Inc. (SNTI)
3.115  -0.105 (-3.26%)    05-22 15:35
Open: 3.0775
High: 3.24
Volume: 15,368
  
Pre. Close: 3.22
Low: 3.07
Market Cap: 81(M)
Technical analysis
2025-05-22 3:20:50 PM
Short term     
Mid term     
Targets 6-month :  4.97 1-year :  5.95
Resists First :  4.25 Second :  5.09
Pivot price 3.23
Supports First :  2.89 Second :  2.4
MAs MA(5) :  3.19 MA(20) :  3.34
MA(100) :  3.71 MA(250) :  3.22
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  28.1 D(3) :  34.7
RSI RSI(14): 42.2
52-week High :  16.94 Low :  1.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SNTI ] has closed above bottom band by 8.3%. Bollinger Bands are 79.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.3 - 3.32 3.32 - 3.33
Low: 3.05 - 3.07 3.07 - 3.09
Close: 3.19 - 3.22 3.22 - 3.24
Company Description

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

Headline News

Thu, 22 May 2025
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - The Manila Times

Thu, 22 May 2025
Senti Bio Cancer Therapy Achieves 71% Response Rate in AML Patients, Secures Additional $1M CIRM Grant - Stock Titan

Tue, 20 May 2025
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

Fri, 16 May 2025
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Tue, 06 May 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI - PR Newswire

Wed, 30 Apr 2025
Shareholders That Lost Money on Senti Biosciences, Inc. (SNTI) Should Contact Levi & Korsinsky About Securities Fraud Investigation - SNTI - ACCESS Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 26 (M)
Shares Float 9 (M)
Held by Insiders 69.3 (%)
Held by Institutions 20.5 (%)
Shares Short 251 (K)
Shares Short P.Month 62 (K)
Stock Financials
EPS 0.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.46
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -36.5 %
Return on Equity (ttm) -116.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -1.32
Sales Per Share 0
EBITDA (p.s.) -1.93
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio 8.41
PEG Ratio 0
Price to Book value 2.13
Price to Sales 0
Price to Cash Flow -1.86
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android